GDF-15 predicts epithelioid hemangioendothelioma aggressiveness and is down-regulated by sirolimus through ATF4/ATF5 suppression.

Silvia Stacchiotti Silvia Martini Sandro Pasquali Anna Maria Frezza Alessia Beretta Stefano Percio Mara Lecchi Monica Tortoreto Marta Barisella Paola Collini Gian Paolo Dagrada Alessandra Merlini Paul H Huang Andrew Jenks Robin L Jones William D Tap Matilde Ingrosso Carlo Morosi Silvia Brich Claudia Giani Paolo Verderio Paolo Giovanni Casali Hugh Leonard Alessandro Gronchi Valentina Zuco Nadia Zaffaroni

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

This study identifies GDF-15 as a novel biomarker of EHE aggressiveness and underscores the superior efficacy of sirolimus compared to doxorubicin in our experimental models. The observed inhibition of GDF-15 release by sirolimus suggests its potential as a biomarker for monitoring the drug's activity in patients.

Keyphrases

end stage renal disease
transcription factor
newly diagnosed
ejection fraction
chronic kidney disease
endoplasmic reticulum stress
prognostic factors
genome wide
gene expression
emergency department
patient reported
drug induced